Impact BioMedical: 60,496,041 common shares from Series A conversion

Impact BioMedical Inc. announced the conversion of its Series A Convertible Preferred Stock into common stock under Section 6 of the Certificate of Designation dated October 30, 2023.

Rhea-AI Filing Summary

Impact BioMedical Inc. announced the conversion of its Series A Convertible Preferred Stock into common stock under Section 6 of the Certificate of Designation dated October 30, 2023. The holder, DSS BioHealth Security, Inc., elected the Optional Conversion permitted seventy-five days after issuance.

Following this election, DSS BioHealth Security, Inc. is deemed the record holder of 60,496,041 shares of the Company’s common stock, $0.001 par value per share. The event was reported as of October 24, 2025.

Insights

Capital markets counsel

Preferred converts into 60,496,041 common; holder named record owner.

The company reports an Optional Conversion of its Series A Convertible Preferred Stock as allowed by Section 6 of the October 30, 2023 Certificate of Designation. The conversion results in common equity issuance tied to the preferred’s terms.

The filing states DSS BioHealth Security, Inc. is deemed the record holder of 60,496,041 common shares after the election. This clarifies ownership and voting/record status arising from the conversion mechanics.

The announcement centers on capital structure and ownership. Any impact on float or control depends on existing outstanding share counts and holder decisions, which are not detailed in the excerpt.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Impact BioMedical (IBO) announce?

The company reported an Optional Conversion of its Series A Convertible Preferred Stock into common stock under Section 6 of the October 30, 2023 Certificate of Designation.

How many IBO common shares are tied to the conversion?

DSS BioHealth Security, Inc. is deemed the record holder of 60,496,041 common shares pursuant to the conversion.

Who is the record holder after the conversion?

DSS BioHealth Security, Inc. is deemed the record holder of the 60,496,041 common shares.

What document governs the conversion terms for IBO?

The Certificate of Designation of Series A Convertible Preferred Stock dated October 30, 2023, specifically Section 6 (Optional Conversion).

When was the event reported?

The report identifies the earliest event date as October 24, 2025.

What does Section 6 (Optional Conversion) permit?

It permits the holder to convert, at any time seventy-five (75) days after issuance, into one share of the company’s common stock per preferred share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/27/2025 - 04:05 PM Learn about SEC filing dates

false 0001834105 0001834105 2025-10-24 2025-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2025

IMPACT BIOMEDICAL INC.

(Exact name of registrant as specified in its charter)

Nevada		001-42212		85-3926944
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1400 Broadfield Blvd., Suite 130 Houston, TX		77084
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (585) 325-3610

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Ticker symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Conversion of Series A Convertible Preferred Stock

As previously disclosed, Impact BioMedical Inc. (the “Company”) filed a certificate of designation of Series A Convertible Preferred Stock, dated October 30, 2023 (the “Certificate of Designation”). Pursuant to Section 6 of that certain Certificate of Designation, DSS BioHealth Security, Inc. has elected to convert the Series A Convertible Preferred Stock into shares of common stock, $0.001 par value per share (the “Common Stock”) of the Company. Section 6 of the Certificate of Designation provides for an Optional Conversion on behalf of the holder at any time seventy-five (75) days after the issuance into one share of the Company’s Common Stock.

In connection with the above, DSS BioHealth Security, Inc. shall be deemed the record holder of the 60,496,041 shares of Common Stock that are issuable pursuant to the aforementioned conversion.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

	IMPACT BIOMEDICAL INC.
Date: October 27, 2025	By:	/s/ Frank D. Heuszel
	Name:	Frank D. Heuszel
	Title:	Chief Executive Officer